News Daily News FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil Michael O'Riordan December 14, 2022
News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Conference News AHA 2022 EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD Todd Neale November 06, 2022
News Conference News AHA 2022 Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions Yael L. Maxwell November 01, 2022
News Conference News ESC 2022 Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR L.A. McKeown August 27, 2022
News Daily News AHA Urges More Home-Based Dialysis in Advanced Kidney Failure Michael O'Riordan August 18, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for July 2022 Todd Neale August 01, 2022
News Daily News Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds Shelley Wood July 25, 2022
News Conference News ESC Heart Failure 2022 Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients Shelley Wood May 23, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Daily News Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis Caitlin E. Cox May 03, 2022
News Daily News Guideline-Directed Therapies Underused in Frail HF Patients L.A. McKeown March 11, 2022